Filing Flows › Comparisons › DWTX vs IBIO
Dogwood Therapeutics vs iBio: DWTX and IBIO compared
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $100K for iBio (Q1 FY26).
Where the money goes: DWTX and IBIO
Dogwood Therapeutics (DWTX) · Q3 2026
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
iBio (IBIO) · Q1 FY26
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Dogwood Therapeutics (DWTX) | iBio (IBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY26 |
| Revenue | $100K | $100K |
| Operating margin | n/m | n/m |
| Net earnings | −$4.9M | −$5.7M |
| Operating cash flow | −$4.6M | −$5.7M |
Questions
Which is bigger, Dogwood Therapeutics or iBio?
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $100K for iBio (Q1 FY26).
More: Dogwood Therapeutics earnings · how Dogwood Therapeutics makes money · iBio earnings · how iBio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 12, 2025). Fiscal quarters can end on different dates. Not investment advice.